LY6E inhibit the entry of different variants of SARS-CoV-2 mediated by the spike protein

doi:10.3969/j.issn.1006-7795.2023.04.023

Abstract

Abstract: Objective To investigate the inhibitory effect of lymphocyte antigen 6 complex, locus E (LY6E), on the entry of （severe acute respiratpry syndrome coronavirus 2, SARS-CoV-2） mediated by the spike protein(S)of different variant strains. Methods Plasmid encoding human angiotensin-converting enzyme 2 (ACE2) molecules was constructed. We established Flp-In T-Rex 293/LY6E inducible expression cell lines and Flp-In T-Rex 293/chloramphenicol acetyltransferase (CAT) inducible expression cell lines, transfected human ACE2 expression plasmid, and detected the expression of ACE2 and LY6E in T-Rex 293 cells by Western blotting. The pseudoviral infection systems of SARS-CoV-2 (Wuhan-Hu-1 strain,D614G variant, Delta variant, and Omicron BA.1, BA.2, BA.2.12.1, BA.3, BA.4/5, BF.7 variant)and Lassa fever virus (LASV) were established to detect the activity of LY6E for inhibiting viral entry by using the luciferase reporter gene. The inhibitory effect of LY6E on SARS-CoV-2 mutant strain spike-mediated syncytium formation was detected by the Nano-Glo^® Live Cell Assay System. We constructed the pseudoviral infection systems of influenza A virus (IAV) to detect the inhibitory effect of LY6E on SARS-CoV-2 and its mutants spike protein-mediated entry by using pseudovirus luciferase reporter gene after amphotericin B treatment.Results Flp-In T-Rex 293/LY6E inducible expression cell line could significantly inhibit the infection of SARS-CoV-2 (Wuhan-Hu-1 strain, D614G strain, Delta strain, and Omicron BA.1 mutantstrain),with statistical differences in relative infection rate between the pseudovirus infection of tetracycline (Tet) treated and non-treated groups(WTpp:t=33.920,P<0.001;D614Gpp:t=31.478,P<0.001;Deltapp:t=30.257,P<0.001; Omicronpp:t=21.041,P<0.001).LY6E significantly inhibited S protein-mediated syncytium formation in different mutant strains of SARS-CoV-2, and the differences in relative fluorescence units between the LY6E-expressing and non-expressing groups were statistically significant (D614G: t=18.90, P<0.001; Delta: t=22.28, P<0.001; BA.1: t=8.995, P<0.001; BA.2: t=13.57, P<0.001; BA.2.12.1: t=15.48, P<0.001; BA.3: t=13.65, P<0.001; BA.4/5: t=16.74, P<0.001; BF.7: t=22.29, P<0.001). Amphotericin B treatment did not alter the inhibitory effect of Flp-In T-Rex 293/LY6E inducible cell line on SARS-CoV-2 (Wuhan-Hu-1strain, D614G strain, Delta strain, and Omicron BA.1 mutantstrain) pseudovirus invasion, nor did it alter the enhancement of IAV infection by LY6E. The difference in the relative infection rate between the IAV pseudovirus infection of tetracycline (Tet) treated and non-treated groups was statistically significant (t=3.343, P<0.05).Conclusions LY6E could significantly inhibit the infection of SARS-CoV-2 wild-type (Wuhan-Hu-1 strain) and multiple variants (D614G strain, Delta strain, and Omicron strain) and amphotericin B did not alter the inhibitory effect of LY6E on SARS-CoV-2(Wuhan-Hu-1strain, D614G strain, Delta strain, and Omicron strain).

Key words: lymphocyte antigen 6 complex, locus E, severe acute respiratory syndrome coronavirus 2, Wuhan-Hu-1 strain, D614G strain, Delta strain, Omicron strain, antiviral effect

CLC Number:

R394

Liu Yongmei, Zheng Shuangli, Chen Danying, Song Yanjun, Li Xinglin, Qiu Yaruo, Song Chuan, Zhang Yuanyuan, Wang Xi, Zhao Xuesen. LY6E inhibit the entry of different variants of SARS-CoV-2 mediated by the spike protein[J]. Journal of Capital Medical University, 2023, 44(4): 652-662.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.04.023

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I4/652

References

［1］ Weiss S R, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus［J］. Microbiol Mol Biol Rev, 2005, 69(4): 635-664.
［2］ Peck K M, Burch C L, Heise M T, et al. Coronavirus host range expansion and Middle East respiratory syndrome coronavirus emergence: biochemical mechanisms and evolutionary perspectives［J］. Annu Rev Virol, 2015, 2(1): 95-117.
［3］ Rota P A, Oberste M S, Monroe S S, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome［J］. Science, 2003, 300(5624): 1394-1399.
［4］ Ksiazek T G, Erdman D, Goldsmith C S, et al. A novel coronavirus associated with severe acute respiratory syndrome［J］. N Engl J Med, 2003, 348(20): 1953-1966.
［5］ Van Boheemen S, De Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans［J］. mBio, 2012, 3(6): e00473-12.
［6］ Zaki A M, Van Boheemen S, Bestebroer T M, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia［J］. N Engl J Med, 2012, 367(19): 1814-1820.
［7］ Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China［J］. Nature, 2020, 579(7798): 265-269.
［8］ Zhou P, Yang X L, Wang X G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin［J］. Nature, 2020, 579(7798): 270-273.
［9］ World Health Organization.WHO Coronavirus (COVID-19) Dashboard［EB/OL］. (2023-01-01)［2023-01-01］.https://covid19.who.int.
［10］ Korber B, Fischer W M, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus［J］. Cell, 2020, 182(4): 812-827.e19.
［11］ Li Q Q, Wu J J, Nie J H, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity［J］. Cell, 2020, 182(5): 1284-1294.e9.
［12］ Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization［J］. Nature, 2021, 596(7871): 276-280.
［13］ Zhang L, Li Q Q, Liang Z T, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron［J］. Emerg Microbes Infect, 2022, 11(1): 1-5.
［14］ Sanders D W, Jumper C C, Ackerman P J, et al. SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation［J］. Elife, 2021, 10: e65962.
［15］ Rajah M M, Hubert M, Bishop E, et al. SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced spike-mediated syncytia formation［J］. EMBO J, 2021, 40(24): e108944.
［16］ Shrestha L B, Foster C, Rawlinson W, et al. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission［J］. Rev Med Virol, 2022, 32(5): e2381.
［17］ Rabbani M A, Ribaudo M, Guo J T, et al. Identification of interferon-stimulated gene proteins that inhibit human parainfluenza virus type 3［J］. J Virol, 2016, 90(24): 11145-11156.
［18］ Zhao X S, Sehgal M, Hou Z F, et al. Identification of residues controlling restriction versus enhancing activities of IFITM proteins on entry of human coronaviruses［J］. J Virol, 2018, 92(6): e01535-17.
［19］ Chen D Y, Hou Z F, Jiang D, et al. GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus［J］. Emerg Microbes Infect, 2019, 8(1): 1511-1523.
［20］ Shu Q, Lennemann N J, Sarkar S N, et al. ADAP2 is an interferon stimulated gene that restricts RNA virus entry［J］. PLoS Pathog, 2015, 11(9): e1005150.
［21］ Liu S Y, Aliyari R, Chikere K, et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol［J］. Immunity, 2013, 38(1): 92-105.
［22］ Zhao X S, Zheng S L, Chen D Y, et al. LY6E restricts entry of human coronaviruses, including currently pandemic SARS-CoV-2［J］. J Virol, 2020, 94(18): e00562-20.
［23］ Yu J Y, Liu S L. Emerging role of LY6E in virus-host interactions［J］. Viruses, 2019, 11(11): 1020.
［24］ Classon B J, Coverdale L. Mouse stem cell antigen Sca-2 is a member of the Ly-6 family of cell surface proteins［J］. Proc Natl Acad Sci U S A, 1994, 91(12): 5296-5300.
［25］ Mao M, Yu M, Tong J H, et al. RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell［J］. Proc Natl Acad Sci U S A, 1996, 93(12): 5910-5914.
［26］ Schoggins J W, Wilson S J, Panis M, et al. A diverse range of gene products are effectors of the type Ⅰ interferon antiviral response［J］. Nature, 2011, 472(7344): 481-485.
［27］ Brown D A, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts［J］. J Biol Chem, 2000, 275(23): 17221-17224.
［28］ Chazal N, Gerlier D. Virus entry, assembly, budding, and membrane rafts［J］. Microbiol Mol Biol Rev, 2003, 67(2): 226-237.
［29］ Lin T Y, Chin C R, Everitt A R, et al. Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction［J］. Cell Rep, 2013, 5(4): 895-908.
［30］ Zhao X S, Guo F, Liu F, et al. Interferon induction of IFITM proteins promotes infection by human coronavirus OC43［J］. Proc Natl Acad Sci U S A, 2014, 111(18): 6756-6761.
［31］ Nie J H, Li Q Q, Wu J J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay［J］. Nat Protoc, 2020, 15(11): 3699-3715.
［32］ Dixon A S, Schwinn M K, Hall M P, et al. NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells［J］. ACS Chem Biol, 2016, 11(2): 400-408.
［33］ Wang H L, Guo S R, Yang H. Rapid quantitative monitoring of SARS-CoV-2 spike protein-mediated syncytia formation using split NanoLuc［J］. J Med Virol, 2022, 94(12): 6073-6077.
［34］ Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor［J］. Cell, 2020, 181(2): 271-280.e8.
［35］ Graham C, Seow J, Huettner I, et al. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant［J］. Immunity, 2021, 54(6): 1276-1289.e6.
［36］ Arora P, Sidarovich A, Krüger N, et al. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination［J］. Cell Rep, 2021, 37(2): 109825.
［37］ Hoffmann M, Zhang L, Pöhlmann S. Omicron: master of immune evasion maintains robust ACE2 binding［J］. Signal Transduct Target Ther, 2022, 7(1): 118.
［38］ Mannar D, Saville J W, Zhu X, et al. SARS-CoV-2 omicron variant: antibody evasion and cryo-EM structure of spike protein-ACE2 complex［J］. Science, 2022, 375(6582): 760-764.
［39］ Cui Z, Liu P, Wang N, et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron［J］. Cell, 2022, 185(5): 860-871.e13.
［40］ Sheikh A, Kerr S, Woolhouse M, et al. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE Ⅱ): a national cohort study with nested test-negative design［J］. Lancet Infect Dis, 2022, 22(7): 959-966.

[1]	Zhang Jianxiong, Li Dandan, Hu Mengmeng, Cheng Xuewei, Dong Ruihua. Relationship between carboxylesterase 1 and carboxylesterase 2 gene expression levels and body mass index, and gene polymorphism analysis [J]. Journal of Capital Medical University, 2023, 44(1): 13-19.
[2]	Dong Lingyue, Wang Yutong. Tracing the evolutionary history of humans——Introduction of the Nobel Prize in Physiology or Medicine 2022 [J]. Journal of Capital Medical University, 2022, 43(5): 804-806.
[3]	Li Wei, Hao Chanjuan. Exploring the etiology of pediatric inherited disorders——Dr. Li Wei's Laboratory [J]. Journal of Capital Medical University, 2020, 41(5): 730-735.
[4]	Luo Jianan, Yang Shufa, Yu Xiuyi, Liu Xin, Chen Zhenwen. Establishment a mesenchymal stem cell line model derived from Klinefelter syndrome fetal umbilical cord [J]. Journal of Capital Medical University, 2019, 40(6): 868-874.
[5]	HUA Bing;YANG Meng-han;CHI Ya-fei;WANG Chao. HEY gene family in mammalian cardiovascular development [J]. Journal of Capital Medical University, 2012, 33(4): 534-537.
[6]	Zhu Wanwan;Wang Shuyan;Wu Di;Xu Yanling;Fu Linlin;Guan Yunqian;Zhang Yu. Comparison between Trypsinization and Collagenase Treatment in Passaging of Human Embryonic Stem Cells [J]. Journal of Capital Medical University, 2008, 29(4): 445-450.
[7]	Liang Kuo;Li Fei . Advances of Study on PSP/reg Geng [J]. Journal of Capital Medical University, 2007, 28(6): 794-797.
[8]	Cai Yanning;Zuo Xiaohong;Liu Shu;Xie Shu;Wen Mei;Chen Biao. Expression Profiling of Per1 Gene in Mouse Striatum Detected Using Real Time RT-PCR [J]. Journal of Capital Medical University, 2006, 27(1): 63-65.
[9]	Wang Zhe;Zhang Jinfeng;Fu Guifang . Effect of Rhizoma Curcumate Zedoariae and Herbra Trifolii Repentis on Apoptosis of Human Lung Cancer Cell Line A549 [J]. Journal of Capital Medical University, 2001, 22(4): 304-305.
[10]	. [J]. Journal of Capital Medical University, 1997, 18(3): 234-234.